59326-04-4

Usage

Uses

Used in Pharmaceutical Industry:
14-((4-Methoxyphenyl)diphenylMethoxy) DaunoMycinone is used as a key component in the preparation of anti-tumor agents. Its chemical properties and structure make it a valuable asset in the development of novel cancer treatments.
As a Daunomycinone (D193850) derivative, 14-((4-Methoxyphenyl)diphenylMethoxy) DaunoMycinone plays a crucial role in the formulation of anti-cancer drugs. Its incorporation into these medications aids in targeting and combating various types of cancer cells, potentially improving patient outcomes and survival rates.

Upstream product

• 24385-10-2 adriamycinone 
• 14470-28-1 mono-4-methoxytrityl chloride 

Downstream Products

• 105444-07-3 7-O-(2,3,5-tri-O-acetyl-β-D-ribofuranosyl)adriamycinone 
• 105444-06-2 14-O-(p-anisyldiphenylmethyl)-7-O-(2,3,5-tri-O-acetyl-β-D-ribofuranosyl)-adriamycinone 
• 105444-06-2 14-O-(p-anisyldiphenylmethyl)-7-O-(2,3,5-tri-O-acetyl-α-D-ribofuranosyl)-adriamycinone 
• 105444-06-2 14-O-(p-anisyldiphenylmethyl)-7-O-(2,3,5-tri-O-acetyl-D-ribofuranosyl)-adriamycinone 
• 93704-17-7 7-O-(3,5-dideoxy-3-trifluoroacetamido-β-D-ribofuranosyl)-14-O-p-anisyldiphenylmethyladriamycinone 
• 93704-18-8 7-O-(3-amino-3,5-dideoxy-α-D-ribofuranosyl)-14-O-p-anisyldiphenylmethyladriamycinone 
• 93704-18-8 7-O-(3-amino-3,5-dideoxy-β-D-ribofuranosyl)-14-O-p-anisyldiphenylmethyladriamycinone 
• 93704-15-5 7-O-(2-acetoxy-3,5-dideoxy-3-trifluoroacetamido-β-D-ribofuranosyl)-14-O-p-anisyldiphenylmethyladriamycinone 
• 93704-15-5 7-O-(2-acetoxy-3,5-dideoxy-3-trifluoroacetamido-α-D-ribofuranosyl)-14-O-p-anisyldiphenylmethyladriamycinone 

Relevant academic research and scientific papers

Synthesis and antitumor activity of 7-O-(3,4-di-O-acetyl-2,6-dideoxy-alpha-L-lyxo-hexopyranosyl)adriamycinone.

The title compound (7), the 3'-acetoxy-4'-O-acetyl analog of adriamycin (doxorubicin), was synthesized in approximately 50% net yield from daunomycinone by bromination at C-14, glycosylation of the product at O-7 with 3,4-di-O-acetyl-2,6-dideoxy-alpha-L-l

Synthesis of adriamycin and 7,9-epiadriamycin

A process for the synthesis of adriamycin and 7,9-epiadriamycin, both active antineoplastic agents, in which 7-deoxydaunomycinone, in either the 9s or racemic (±) form, is employed as the starting material, the process in one embodiment also being productive of the useful intermediate compound 4-methoxy-6,11-dihydroxy-7,8-dihydro-5,9(10H),12-naphthacenetrione. The process involves converting 7-deoxydaunomicinone successively to daunomycinone, adriamycinone, 14-0-p-anisyldiphenylmethyladriamycinone and finally to adriamycin or to both adriamycin and 7,9-epiadriamycin. When producing the latter mixture of diastereomers, the 7-deoxydaunomycinone starting material is first converted to racemate form by a process involving the successive production of 7-deoxydaunorubicinol, 4-methoxy-6,11-dihydroxy-7,8-dihydro-5,9(10H), 12-naphthacenetrione, (±)-4-methoxy-9-cyano-6,9,11-trihydroxy-7,8,9,10-tetrahydro-5,12-naphthacenedione, (±)-4-methoxy-9-cyano-9-(2'-tetrahydropyranyloxy)-6,11-dihydroxy-7,8,9,10-tetrahydro-5,12-naphthacenedione and (±)-7-deoxydaunomycinone.